BRACNAC: A BRCA1 and BRCA2 Copy Number Alteration Caller from Next-Generation Sequencing Data
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242316630 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Andrey Kechin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Biology and Fundamental Medicine, Novosibirsk 630090, Russia. Hauptthemen laut MEDLINE: DNA Copy Number Variations, Ovarian Neoplasms, Prostatic Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian State funded budget project, Fundamentals of Health Preservation.
Abstract (Originalsprache)
Detecting copy number variations (CNVs) and alterations (CNAs) in the BRCA1 and BRCA2 genes is essential for testing patients for targeted therapy applicability. However, the available bioinformatics tools were initially designed for identifying CNVs/CNAs in whole-genome or -exome (WES) NGS data or targeted NGS data without adaptation to the BRCA1/2 genes. Most of these tools were tested on sample cohorts of limited size, with their use restricted to specific library preparation kits or sequencing platforms. We developed BRACNAC, a new tool for detecting CNVs and CNAs in the BRCA1 and BRCA2 genes in NGS data of different origin. The underlying mechanism of this tool involves various coverage normalization steps complemented by CNV probability evaluation. We estimated the sensitivity and specificity of our tool to be 100% and 94%, respectively, with an area under the curve (AUC) of 94%. The estimation was performed using the NGS data obtained from 213 ovarian and prostate cancer samples tested with in-house and commercially available library preparation kits and additionally using multiplex ligation-dependent probe amplification (MLPA) (12 CNV-positive samples). Using freely available WES and targeted NGS data from other research groups, we demonstrated that BRACNAC could also be used for these two types of data, with an AUC of up to 99.9%. In addition, we determined the limitations of the tool in terms of the minimum number of samples per NGS run (≥20 samples) and the minimum expected percentage of CNV-negative samples (≥80%). We expect that our findings will improve the efficacy of BRCA1/2 diagnostics. BRACNAC is freely available at the GitHub server.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Biology and Fundamental Medicine, Novosibirsk 630090, Russia.
- Faculty of Natural Sciences, Novosibirsk State University, Novosibirsk 630090, Russia.
ORCID-Profile: Andrey Kechin, Ulyana Boyarskikh, Sergey Subbotin
Förderung
- Russian State funded budget project
- Fundamentals of Health Preservation
Zitieren
APA
Kechin, A., Boyarskikh, U., Borobova, V., Khrapov, E., Subbotin, S., & Filipenko, M. (2023). BRACNAC: A BRCA1 and BRCA2 Copy Number Alteration Caller from Next-Generation Sequencing Data. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316630
Vancouver
Kechin A, Boyarskikh U, Borobova V, Khrapov E, Subbotin S, Filipenko M. BRACNAC: A BRCA1 and BRCA2 Copy Number Alteration Caller from Next-Generation Sequencing Data. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316630
BibTeX
@article{Kechin2023,
author = {Kechin, Andrey and Boyarskikh, Ulyana and Borobova, Viktoriya and Khrapov, Evgeniy and Subbotin, Sergey and Filipenko, Maxim},
title = {BRACNAC: A BRCA1 and BRCA2 Copy Number Alteration Caller from Next-Generation Sequencing Data},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242316630}
}
EUVIMED